Cargando…
Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
Colorectal cancer (CRC) is the third most common cancer type in both men and women in the USA. Most patients with CRC are diagnosed as local or regional disease. However, the survival rate for those diagnosed with metastatic disease remains disappointing, despite multiple treatment options. Cancer t...
Autores principales: | Wookey, Vanessa, Grothey, Axel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246487/ https://www.ncbi.nlm.nih.gov/pubmed/34262612 http://dx.doi.org/10.1177/17562848211024460 |
Ejemplares similares
-
Advances in immunotherapy for colorectal cancer: a review
por: Golshani, Gol, et al.
Publicado: (2020) -
Evolution of colorectal cancer screening research in the past 25
years: text-mining analysis of publication trends and topics
por: Soffer, Shelly, et al.
Publicado: (2020) -
The association between circulating levels of vitamin D and
inflammatory markers in the first 2 years after colorectal cancer
diagnosis
por: Wesselink, Evertine, et al.
Publicado: (2020) -
Chemotherapy and Targeted Therapy Strategies in Patients with Unresectable or Borderline Resectable Metastatic Colorectal Cancer: Evidence for a Lack of Focus on Resection Rates
por: Zmuc, Jan, et al.
Publicado: (2023) -
Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future
por: Sargent, Daniel, et al.
Publicado: (2010)